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Cryptosporidium is a common protozoan parasitic cause of diarrhoea in children 2 
worldwide. In those with profound T-cell immunodeficiency, including haematopoietic 3 
stem cell transplant (HSCT) recipients, it can cause protracted disease which may be 4 
fatal1,2. Its role in sclerosing cholangitis in patients with dedicator of cytokinesis 8 5 
(DOCK 8) deficiency has been highlighted3. Specific treatment options are limited, 6 
with no licensed treatment in the EU; in the US, treatment with nitazoxanide is 7 
licensed for immunocompetent patients. There is no evidence for its efficacy in 8 
immunocompromised patients4. Some young children display asymptomatic 9 
Cryptosporidium carriage5,6 which may precede symptomatic disease in vulnerable 10 
groups2. Detecting asymptomatic carriage and some symptomatic cases may require 11 
more sensitive methods than microscopy of stained smears, such as PCR, 12 
immunofluorescence microscopy (IFM), or immuno-magnetic separation (IMS)-13 
IFM2,6,7 , methods used by very few carriage studies.  14 
 15 
This report describes a prospective cohort study of children with primary 16 
immunodeficiencies undergoing HSCT in the UK. The study objectives were to use 17 
highly sensitive methods to investigate the extent of carriage of Cryptosporidium and 18 
its clinical significance in this high-risk group of patients.  19 




Over a two-and-a-half year period, all children <18 years old with primary 22 
immunodeficiencies undergoing HSCT at the paediatric bone-marrow transplant 23 
(BMT) units at the Royal Victoria Infirmary, Newcastle-upon-Tyne and Great Ormond 24 
Street Children’s Hospital, London were eligible for inclusion in the study. Between 25 
them, these two centres perform the vast majority of BMTs in this patient group for 26 
the UK and Ireland. 27 
 28 
Informed consent to participate in the study was obtained from patients and/or their 29 
guardians. Clinical patient data was supplied by the clinical team caring for the 30 
patients by means of a structured questionnaire. Possible risk factors for exposure 31 
were obtained from families, who filled in a questionnaire which asked about the 32 
following risk factors: travel history, number of children living in same household, 33 
water supply at home (mains supply, private supply or group water scheme if in 34 
Ireland), whether drinking water had been boiled, swimming, pets, farm visits, nature 35 
and duration of childcare and school attendance. Stools from all study participants 36 
were collected prior to transplant and tested by routine microscopy (with modified 37 
Ziehl-Neelsen or Auramine phenol staining)  in the local diagnostic laboratory and 38 
then in all cases by specialist tests at the national Cryptosporidium Reference Unit as 39 
follows: IFM (Crypto-Cel, Cellabs); PCR (SSU rRNA gene)8; IMS-IFM (Isolate, TCS 40 
Biosciences; Crypto-Cel, Cellabs)7. In stools found to be Cryptosporidium-positive 41 
the species and subtype was confirmed by sequencing PCR products amplified from 42 
the SSU rRNA and gp60 genes8. Repeat samples were tested at 2 months post-43 
transplant, and again at 3 months after the end of immunosuppression (to give the 44 
patient a chance to clear carriage). Specimens were also tested on clinical grounds 45 
whenever a patient had symptoms consistent with cryptosporidiosis. Clinical and 46 
patient follow-up data were collected. 47 
  48 
3 
 
Results  49 
Forty-two patients undergoing BMT for primary immune deficiency were recruited: 34 50 
from the UK, 7 from the Republic of Ireland and one from Norway. The age range 51 
was 1 month to 17 years; median 2.5 years, mean 7.4 years (10 children aged <1 52 
year, 8 children aged 1-2 years, 8 children aged 2-5 years, 16 children aged 7-17 53 
years). The underlying diagnoses were: Severe Combined Immune Deficiency 54 
(SCID) (8 children), Chronic Granulomatous Disease (7), CD40 ligand deficiency (5), 55 
Hemophagocytic lymphohistiocytosis (3), DOCK 8 deficiency (2), combined 56 
immunodeficiency syndrome (2), Omenn’s syndrome (2), immune dysregulation, 57 
polyendocrinopathy, enteropathy, X-linked (IPEX)-like syndrome (2), one with each of 58 
Cartilage Hair Hypoplasia, X-linked lymphoproliferative (XLP)-like syndrome, 59 
immunodeficiency, centromeric region instability, and facial anomalies (ICF) 60 
syndrome, Fas-associated death domain protein (FADD) deficiency, osteopetrosis, 61 
Wiskott-Aldrich syndrome, 2 with complex autoimmune disease, 3 unclassified. 62 
 63 
Three patients were found to be infected with Cryptosporidium. The presentation and 64 
clinical impact of the disease in these three cases were very different from one 65 
another. One patient (case 1) was infected with Cryptosporidium parvum (subtype 66 
IIaA19G4R1). This case was a 17 year old male from Ireland who had first presented 67 
at the age of 5 years. The presentation and course of his undefined combined 68 
immunodeficiency resembled CD40 Ligand deficiency although this was excluded. At 69 
the age of 8 years he had developed hepatosplenomegaly, diarrhoea and 70 
cholangiohepatitis. At that time his stools were consistently negative for 71 
Cryptosporidium by microscopy at his local microbiology laboratory. However a liver 72 
biopsy revealed histological evidence of Cryptosporidium and advanced liver 73 
disease. 74 
 75 
Eventually three years later C. parvum (subtype IIaA19G4R1) was detected in a 76 
small bowel aspirate and subsequently was detectable intermittently in stool 77 
samples. He suffered severe disease attributable to the infection, leading to 78 
cholangitis and liver cirrhosis. At the age of 14 years he underwent a liver transplant. 79 
Six weeks later HSCT was performed. His first liver was rejected but a second 80 
transplant at age 15 was successful. He was treated with nitazoxanide and 81 
azithromycin throughout (unlicensed indications). His stools remained positive for 82 
Cryptosporidium a few months after his second liver transplant and he continued on 83 
nitazoxanide for almost two years after that, in view of his immunosuppressant 84 
treatment, and concern about the new liver becoming infected. Long term 85 
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azithromycin was continued as part of his routine post-HSCT antibacterial 86 
prophylaxis.  He had a number of risk factors for Cryptosporidium infection, most 87 
notably drinking unboiled water from the household private water supply, and living 88 
on a farm where he came into direct contact with cows and sheep.  89 
 90 
Two cases had Cryptosporidium hominis but, surprisingly, did not appear to suffer 91 
clinical disease. One (case 2) was an 11 year old girl from the UK and the other 92 
(case 3) a 7 year old boy from Ireland, both with DOCK 8 deficiency. In both, stool 93 
screening by microscopy pre-transplant was negative. In case 2, stool screening was 94 
positive for C. hominis at seven weeks post–HSCT when her CD4 count was 102 95 
cells/mm3, but the patient was asymptomatic. She was nonetheless treated with 96 
azithromycin and nitazoxanide for 1 week (unlicensed indication). Treatment was 97 
then discontinued and the patient’s CD4 counts rose to 586 cells/mm3 within two 98 
more weeks. Her risk factors for C. hominis included contact with three younger 99 
siblings and infrequent use of swimming pools. She drank unboiled tap water from a 100 
mains supply. Four weeks after the first positive sample, stool microscopy was 101 
negative although still positive for Cryptosporidium by PCR. In case 3, routine 102 
screening locally by microscopy revealed presence of Cryptosporidium (identified as 103 
C. hominis) four weeks post-transplant when CD4 count was 387 cells/mm3. This boy 104 
was also asymptomatic. He was treated for one week with azithromycin (unlicensed 105 
indication). CD4 count reached 479 cells/mm3 two weeks later. Stool remained 106 
positive for Cryptosporidium by both microscopy and PCR for eight weeks after 107 
infection but became negative after ten and fifteen weeks respectively. He had been 108 
in the UK for four months, during which time he drank only boiled/filtered water. Risk 109 
factors for C. hominis included one younger sibling, using swimming pools (though 110 
not in the year prior to stool sampling), and attendance at day nursery and 111 
childminder for two years before starting school.  112 
 113 
Typically one would expect to find more severe disease in this vulnerable group but 114 
the identification of these cases may indicate that asymptomatic carriage is more 115 
common than currently believed, and is perhaps under-detected. These two cases 116 
presented within one month of each other in the same transplant unit. However, 117 
different gp60 subtypes were identified: IbA10G2 and IfA13G1, a finding which did 118 
not support the occurrence of transmission between these two patients within the 119 
unit. Increased observation and testing of the 9 patients on the unit at that time 120 
detected no further Cryptosporidium cases either clinically or microbiologically by 121 






Three of the cases (3/42; 7%) were found to be infected with Cryptosporidium, more 126 
than 5 times the proportion detected using the same techniques among healthy 127 
children in a UK study of young children attending day-care settings6. All three cases 128 
occurred in children in the older age range (8, 11 and 7 years at first presentation). In 129 
developed countries, infants and children aged less than 2 years may be less likely to 130 
have been exposed to Cryptosporidium, particularly if they have presented with 131 
immune deficiency at a very young age and provided with precautionary advice. If 132 
cases aged <2 are excluded from the analysis, 3/24 (12.5%) were infected. 133 
 134 
In a previous study by Mclauchlin et al2, 12 of 25 (48%) children with primary 135 
immunodeficiencies tested prospectively were reported positive by PCR (but not 136 
microscopy) for Cryptosporidium – a much higher proportion than found in our study. 137 
They were of a relatively older age group than our series but nonetheless the 138 
proportion infected was about four times that in our cohort even after excluding the 139 
under-twos.  Mclauchlin’s cases were studied 10-15 years prior to our study when UK 140 
drinking water supply quality was not as good, and there was lower awareness of the 141 
risk of Cryptosporidium to this patient group. Since that time, the Water Supply 142 
(Water Quality) Regulations of 2000 were introduced and an associated decline in 143 
cryptosporidiosis has been demonstrated9. Additionally, these high risk patients have 144 
been managed with strict advice on avoiding Cryptosporidium10. In Mclauchlin’s 145 
cohort the children became sicker during transplant as a result of cryptosporidiosis. 146 
This might at least partly be explained by changes in the intensity of chemotherapy 147 
conditioning. However the underlying diagnosis may also be relevant. In 148 
McLaughlin’s study, nearly half (46%) had CD40 ligand deficiency; in ours it was only 149 
5/42 (12%). Of our three cases, the case resembling CD40 ligand deficiency was 150 
most severely affected. The worst affected child also had C. parvum infection whilst 151 
the other two were infected with C. hominis, although the numbers in this study are 152 
too small to draw any conclusion regarding prognosis by infecting species of 153 
Cryptosporidium.  154 
 155 
Whilst overall only 1/34 of study patients from the UK were infected with 156 
Cryptosporidium, 2/7 of those from Ireland were affected. The numbers in this study 157 
are small, however a study including more patients would be lengthy, since given the 158 
rarity of these conditions our patients took two years to recruit. Regulations 159 
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supporting the European Drinking Water Directive and water safety plan approach 160 
are now being implemented in both countries.  161 
 162 
Conclusions 163 
This study provides an indication of the current frequency and presentation of 164 
cryptosporidiosis within this patient group, and of geographical issues to consider as 165 
to a patient’s origin during initial assessment. Screening may be justified for patients 166 
from some locations; however specialist pre-HSCT stool screening did not result in 167 
any change in patient management in this series. Although patients are at risk of 168 
infection post-transplant, lower intensity conditioning may have limited the clinical 169 
significance provided the immune system is recovering.  170 
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